Great things are coming soon.
At epm Therapeutics, we strive for innovation. Thank you for your patience as we improve our website. In the meantime, please browse the available resources below.
About Us
Our Mission
epm Therapeutics is a biotechnology company developing synthetic cannabinoid acid derivatives. Our singular dedication is researching and developing the potential of our EPM301 to improve the symptoms of hyperphagia (uncontrolled appetite) in patients with PWS (Prader-Willi Syndrome) and improve their quality of life as well as that of their dedicated caregivers.
Our History
epm was founded in 2017 by a group of entrepreneurs in collaboration with the Hebrew University in Jerusalem. Asaf Ohana, one of the group, suffered severe injuries during his time as an Israeli combat soldier and, over a period of five years, underwent extensive surgery and rehabilitation, during which he experienced the benefits of breakthrough CBD treatments, and became intrigued with their therapeutic potential.
Asaf, and others who shared his vision, embarked on a mission to fully understand how CBD might be developed to potentially improve the quality of life for patients with unmet medical needs. This journey took them to the Hebrew University of Jerusalem and the laboratory of the globally recognized
"godfather of cannabis research,” Professor Raphael Mechoulam who had devoted his career to uncovering the potential benefits of cannabis and its active constituents. This meeting led to the formation of epm, which in the early stages, worked alongside Prof. Mechoulam with a focus on the isolation, stabilization, and pre-clinical evaluation of a series of cannabidiol acids.
Professor Mechoulam passed away in March of 2023, and along with the rest of the world, epm salutes his incredible contributions and his lifelong dedication to discovery.
epm was restructured in 2023 and is today doing business as epm Therapeutics.
Our Development
EPM301 (synthetic cannabidiol acid methyl ester) is our lead development candidate and was recently granted Orphan Drug Designation by the US FDA for the treatment of hyperphagia in patients with Prader-Willi Syndrome, a rare disease affecting 10,000-20,000 individuals in the US with a market potential estimated to be more than $US500M.
Our Team
epm's Management Team comprises four credentialed and highly experienced individuals with over 80 years of global experience in R & D, Financing and Commercialization who are solely focused on achieving an IND filing for EPM301 in PWS within 5 Quarters from the completion of the Seed Round of investment.
Peter Welburn, Ph.D.
A senior pharmaceutical executive with over 30 years of international experience in R&D roles and general management in Biotech and Pharmaceutical companies. From 2011 to 2014 Dr. Welburn served as the General Manager of LEO Pharma Australia & New Zealand following the acquisition of Peplin by LEO Pharma.
Phil Rose, R.Ph.
Phil has held operational positions in the United States of increasing responsibility in sales, marketing, and administration for pharmaceutical companies such as Eli Lilly, GSK (VP Hospital Sales), Bausch Health (Vice President and General Manager for North America), and Obagi (President and CEO). Phil specializes in financial and product development strategy to maximize commercial potential. Phil is also a practicing Registered Pharmacist.
Joseph Tam, Ph.D.
Prof. Tam is a world-renowned leader in the field of cannabis-based solutions. He is Head of the Obesity and Metabolism Laboratory at the Hebrew University of Jerusalem and Head Director of the Multidisciplinary Center of Cannabinoid in Israel. Prof. Tam received the NCATS Director's Award from the National Institute of Health, and the Chowers Prize for Endocrinology by the Israel Endocrinology Society.
Jaime Rodriguez
Mr. Rodriguez is a result driven industry agnostic executive with extensive knowledge across multiple geographies. Has proven experience in world-class companies as a consultant at Bain & Company and as Chief Strategy Officer in publicly traded organizations. Mr. Rodriguez serves on several Boards of Directors and Advisory Committees sharing knowledge with entrepreneurs and businessmen. Currently is the General Manager at family office for one of Mexico´s prominent families.
Downloadable Resources
Make a change with us.
We are looking for investors that are committed to building a better tomorrow.
To learn how you can get involved, contact us below.
Contact Us
